Autism Spectrum Disorder: A Systematic Review on how Diagnosis, Treatment, and Etiology have been considered in Brazil

Eduardo Listik^{a,b}, Marcia Listik^c

^a Department of Biochemistry, Universidade Federal de São Paulo. Rua Três de Maio, 100, São Paulo, SP, Brazil, CEP: 04044-020.

^b Department of Pathology, University of Alabama at Birmingham, Birmingham AL, USA, 35294

^c Listik Neuro Serviços Médicos, São Paulo, SP, Brazil. Rua Afonso Celso, 1629 cj. 42, São Paulo, SP, Brazil, CEP: 04119-062

Short Title: Autism spectrum disorder: a perspective in Brazil

Corresponding Author:

Eduardo Listik, Ph.D.

WTI 330F, 1824 Sixth Avenue South,

Birmingham, AL, 35233.

E-mail: elistik@uabmc.edu

Phone: +1-205-934-6980/1

Keywords: Autism disorder; Diagnosis; Therapeutics; Brazil

Disclosures and Declaration: Conflict of Interest: The authors declare that there is no conflict of interest regarding the publication of this article. / Ethical Approval: This article does not contain any studies with human participants or animals performed by any of the authors. / Informed Consent This article does not involve the use of human subjects.

Data transparency: All the generated datasets in this study are available from the corresponding author upon reasonable request.

1 **ABSTRACT**

2 Autism spectrum disorder is a group of developmental disorders whose clinical characteristics
3 include socialization impairment, language disability, and unusual behavior. This review aimed
4 to analyze how the Brazilian community researches autism, seeking answers surrounding its
5 treatment, etiology, and diagnosis. The search for publications was based in Elsevier's Scopus
6 Database in June 2019 and was focused on the study of autism in Brazil or with Brazilian data.
7 We categorized publications on diagnosis, treatment, and etiology. The majority of the
8 publications found after inclusion/exclusion criteria sought to validate and adapt pre-existing
9 scales to the Brazilian Portuguese. Instead, the groups performing these studies have had little
10 background in the biochemical, genetic, or environmental aspects of the disease in the country.

11 INTRODUCTION

12 Autism spectrum disorder (ASD) is a group of developmental disorders that begins,
13 typically, in children below three years. Clinical characteristics of ASD include socialization
14 impairment, language disability, and unusual behavior (e.g., running back and forth, flapping,
15 spinning around) (Park et al. 2016). ASD has become more frequent: in 2012, 1.5% of people in
16 the United States were diagnosed with the disorder (Graf et al. 2017).

17 There is difficulty in diagnosing ASD as there are no alternative assessments besides
18 clinical evaluation. The health professionals make use of diagnostic tools such as behavior
19 scales in order to facilitate and quantify clinical findings. There are several scales focused on
20 autism, including the ones validated to Brazilian Portuguese such as the Childhood Autism
21 Rating Scale (CARS), the Autism Behavior Checklist (ABC), the Autism Screening
22 Questionnaire (ASQ), the Autism Diagnostic Interview-Revised (ADI-R), the Autistic Traits
23 Assessment Scale (ATA), and the Modified Checklist for Autism in Toddlers (M-CHAT)
24 (Pereira et al. 2008; Marteleto and Pedromonico 2005a; Sato et al. 2009; Becker et al. 2012;
25 Assumpção Jr. et al. 1999; Losapio and Pondé 2008).

26 This review aimed to analyze how the Brazilian community researches autism, and it
27 seeks answers for its treatment, etiology, and diagnosis.

28

29 METHODS

30 Database and Literature Retrieval

31 The search for publications was conducted in Elsevier's Scopus Database in June 2019.
32 The precise input was “((TITLE ("autism" AND "Brazil") OR ABS ("autism" AND "Brazil"))
33 AND PUBYEAR > 2008”, which translates the terms *autism* and *Brazil* being present in the
34 title or abstract of articles published only from 2009 on.

35 The search yielded in 67 results, which were screened for eligibility with inclusion and
36 exclusion criteria before further analysis.

37 Inclusion Criteria

Articles that focused on the study of autism in Brazil or with Brazilian data were primarily retained in our sample, but we only included researches that had an appeal towards *diagnosis* (either through validated scales, genetic tests, or metabolic biomarkers) and *treatment* (both pharmacological and non-pharmacological approaches) We also considered works that had perspectives on ASD *etiology*.

Exclusion Criteria

Observational, psychosocial, educational, or behavioral assessment researches were not kept in this study's sample. Additionally, articles presenting data with autism-like behavior through lesions of the central nervous system or prematurity and articles without methodological controls were also excluded.

RESULTS

Study Selection

The search resulted in 67 hits of which only 60 were related to the topic. After a screening of the abstract texts of all these articles, 37 articles were not within our context and were excluded. The remaining 23 were thoroughly read for eligibility assessment, and 10 were excluded: 5 for not presenting methodological controls, 1 for displaying exclusion criteria, 2 for not displaying the inclusion criteria, and 2 for not being fully ASD-related (Figure 1). The remaining 13 articles are described in Table 1.

Synthesis of Results

Diagnosis

Based on our selection, 69% of the articles focused on diagnosis, with 78% of those aimed at validating or adapting a set of scales for autism to Brazilian Portuguese. The other two articles on diagnosis had perspectives on the difficulties of performing a diagnosis of ASD patients of young ages or assessing genetic variation that may (or may not) contribute to autism.

Sato et al. (2009) translated, culturally adapted, and validated the Autism Screening Questionnaire (ASQ) for Brazilian Portuguese (Sato et al. 2009). The validation process included groups of 40 patients, either with a pervasive developmental disorder (PDD), Down

Syndrome (DS), or other psychiatric or mental disorders. ASQ has 40 questions, and a score cut-off of 15 indicates a high sensitivity (92.5%) and specificity (95.5%) for PDD alone, distinguishing it from other mental and psychiatric disorders. The study also briefly compares these results from two other previously-validated scales, ATA and ABC (Assumpção Jr. et al. 1999; Marteleto and Pedromonico 2005a), and notes that, unlike ASQ, these scales have been poorly used in the scientific literature; ASQ itself has proven a reliable tool to distinguish PDD from non-PDD cases (DS and other psychiatric or mental disorders).

The Autism Diagnostic Interview-Revised (ADI-R) was first translated and transculturally validated by Becker et al. (2012) (Becker et al. 2012). Their study included 20 patients with autism and 20 patients who did not have the disease but had an intellectual disability. ADI-R contains 93 items, which are presented in an interview to caregivers of possible ASD patients, and it has four scores (A to D), whose cut-offs are 10, 8, 3 and 1, respectively (Lord et al. 1994). The validated scale had high discrimination, revealing a sensitivity and specificity of 100% while *maintaining* the previous cut-off from the English version. The study also mentions that ADI-R is considered a valuable source for autism diagnosis and is frequently used as a clinical instrument (Moss et al. 2008; Gray et al. 2008). It reports that, although 30% of patients with moderate intellectual disability do score in some diagnostic domains of the assay, the study can discretize the groups with confidence (Lord et al. 1994).

The studies found were not only about the validation of scales: Canabarro et al. (2018), for instance, focused solely on translating and adapting the Autism Self-Efficacy Scale for Teachers (ASSET) (Canabarro et al. 2018). This scale possesses 30 items and is intended to inform how teachers may direct themselves towards students with autism (Ruble et al. 2013). The study observes that teachers feel uneasy educating ASD children, primarily due to the variety of symptoms, and it is implied that the use of self-efficacy scales such as ASSET may assist educators in such contexts.

Marques et al. (2015), providing an additional perspective, contributed a study modifying and validating the *Protocolo de Avaliação para Crianças com Suspeita de*

94 *Transtornos do Espectro do Autismo* (PRO-TEA) (Marques and Bosa 2015). Their subjects
95 were analyzed retrospectively, being divided into three groups of 10 individuals: (i) ASD
96 children, (ii) children with Down syndrome, and (iii) controls. The results demonstrate that the
97 tool may differentiate, among some of its items, ASD children from their controls. Nevertheless,
98 there are still efforts to develop its capacities further, and an investigation is ongoing regarding
99 its sensibility, sensitivity, and other statistics.

100 Additionally, Bara et al. (2018) promoted more significant insights regarding two
101 different scales for Autism in Brazilian Portuguese that were pending further validation: the
102 Child Behavior Checklist (CBCL) and the Caregiver-Teacher's Report Form (C-TRF) (Bara et
103 al. 2018). Both scales are questionnaires to be completed by the caregiver/educator of ASD
104 children (from 1.5–18 years) in order to analyze behaviors and indicators of mental disorder
105 (Havdahl et al. 2016; Biederman et al. 2010). Bara et al.'s analysis indicated that CBCL had
106 inferior sensitivity (53.3%) and moderate accuracy, leading to a significant number of false
107 negatives. On the other hand, CBCL demonstrated higher sensitivity (80.6%) and specificity
108 (71.8%). Ultimately, this study acknowledges that the lack of precision in both scales may arise
109 from selection issues with the control group, which contained a variety of behavioral disorders
110 that may have influenced the high false-negative rates.

111 Backes et al. (2014), on the other hand, performed a very interesting review of the
112 various tools that have been validated for the Brazilian Portuguese and assessed their
113 perspective on ASD (Backes et al. 2014). The review presents six ASD assessment tools that
114 have been validated in Brazilian Portuguese: ABC, ADI-R, ASQ, ATA, CARS, and M-CHAT.
115 It suggests that the M-CHAT was the best-adapted tool and that all six instruments had
116 acceptable internal consistency values. During validation, ASQ, ADI-R, and ABC displayed
117 sensitivity levels above 90%. The authors ultimately name M-CHAT the most reliable tool for
118 ASD assessment and express a desire that more diagnostic instruments be developed to improve
119 clinical practice in Brazil.

120 Lastly, Seize et al. (2017) is the last study we encountered that focused on how the use
121 of scaling tools may assist diagnostics. This work focuses in particular on instruments that may

122 assist the detection of early signs of autism (prior to 36 months) (Seize and Borsa 2017). The
123 study reports that, although 11 instruments were found for that purpose, only one (M-CHAT)
124 has been validated in Brazilian Portuguese. The authors point out, similarly to Backes &
125 colleagues (2014)(Backes et al. 2014), that this is an alarming landscape: either validation of
126 pre-existing tools or novel tools is needed to assist in the early diagnosis of ASD children, and
127 lack thereof hampers their opportunities to improve the patient clinical perspective among
128 different intervention programs.

129 Following this context of the scaling tools in ASD, Table 2 summarizes the main
130 statistical characteristics of the scales that were mentioned or present in the studies in this
131 review.

132 Two additional works aimed at the diagnostics of ASD in Brazil were not focused on
133 scaling tools but rather two distinct essential questions. Santos et al. (2010) evaluated a
134 polymorphism (C677T) in the methylenetetrahydrofolate reductase (*MTHFR*) enzyme's gene to
135 link it potentially with ASD (dos Santos et al. 2010). The study comprised 151 ASD patients
136 and 100 control individuals, who were tested in the South of Brazil, and concluded that this
137 polymorphism alone could not be associated with the disorder. The work also states that several
138 other attempts have been made to draw this connection to *MTHFR*. Nevertheless, the literature
139 presents a handful of mixed conclusions that sometimes indicate that this polymorphism is
140 associated with ASD and other times indicate that it is not (Pasca et al. 2009; Goin-Kochel et al.
141 2009). As a spectrum, autism is a complex disease, in which biomarkers are complex to
142 establish.

143 From another perspective, Ribeiro et al. (2017) studied parental dynamics in Brazil,
144 from initial concerns about a possible ASD diagnosis to receiving communication of it from a
145 professional. The group interviewed 19 mothers who had children diagnosed with ASD. The
146 research uncovered that the parents had primary concerns in the first two years of their child's
147 life, but the concrete diagnosis would only be achieved about three years later. The primary
148 reason cited for the delay was typically the unpleasant or dismissive experiences that the parents

149 would have with health professionals, particularly pediatricians. The conclusion concurs with
150 Seize et

151

152 *Treatment*

153 A small portion of the studies examined aspects of treatment for ASD patients in Brazil.

154 Hsia et al. (2014) is a study from a Chinese group that investigated the prescription
155 pattern of psychotropic drugs intended for ASD patients' therapy in an international scope (Hsia
156 et al. 2014). The study analyzed a total of 11 countries, including Brazil, and verified some
157 curious discrepancies. Brazil and Mexico most rarely prescribe psychotropic drugs, as opposed
158 to the highest prescription rates in the USA and Canada. The countries studied mainly utilized
159 risperidone in ASD children, except for the United Kingdom (methylphenidate) and Japan
160 (haloperidol). In Brazil, aside from risperidone (55.7%), other notable drugs in use were
161 quetiapine (7.7%) and carbamazepine (6.7%). It is suggested that some of the diverse
162 prescription profiles may relate to varied aspects of each countries' health care systems,
163 physician specialties (e. g., pediatricians, psychiatrists, general practitioners), and cultural
164 differences (Murray et al. 2014; Zito et al. 2008).

165 In another treatment perspective, Nunes and Walter (2018) recently reviewed how
166 Augmentative and Alternative Communication (AAC) may be used as a cognitive development
167 tool for individuals with ASD in Brazil. AAC is, in synthesis, the supplementation of natural
168 speech and writing through aided or unaided strategies in order to promote communication
169 enhancement (Nunes and Walter 2018). The study did conclude that the use of this method is
170 little-explored in Brazil to date: professionals feel ill-prepared to apply it, and the newer models
171 and approaches proposed are not being fully explored as to solidify it as a reproducible method.

172 Considering these newer strategies, Goulart et al. (2017) proposed to review how the
173 use of touchscreen input devices and their software applications have been employed for
174 Brazilian ASD children (Goulart et al. 2017). It has been demonstrated that these tools have
175 become valuable for teaching academic skills, communication skills, leisure skills, transitioning,
176 and developing employment skills in ASD children around the world (Kagohara et al. 2013).

177 The study revealed that the therapeutic researches of touch technology on ASD children are
178 concentrated in the South of Brazil, which reported evidence that the use of software
179 applications is favorable for ASD children, leading to improvement in behavior,
180 communication, and stereotypical movements.

181

182 *Etiology*

183 Only a single publication within our criteria was found to address the etiology of ASD
184 in Brazil. Maia et al. (2018) investigated, retrospectively, whether the genitor age, either
185 maternal or paternal, could influence the onset of ASD on their children (Maia et al. 2018).
186 They compared 243 ASD patients' cases with 886 controls and identified that both maternal and
187 paternal ages influence this context, although the former may be more prominent than the latter.
188 The authors argue that both genomic and environmentally-acquired epigenetic alterations
189 become more frequent with aging, and these changes are passed to possible offspring (Puleo et
190 al. 2012; Zhubi et al. 2014).

191

192 **DISCUSSION**

193 Our study aimed to review how crucial aspects of ASD have been viewed in Brazil over
194 the last ten years. We searched in the Scopus database and retrieved a total of 67 publications,
195 but after inclusion and exclusion criteria, only 13 were left for analysis, a rather small sample
196 for such a vital theme (Murphy et al. 2016).

197 As an overall search, for the last ten years worldwide, *autism* yielded 13,501 hits;
198 *autism* and *treatment* 6,748 (Volkmar et al. 2014; Bauman 2010), *autism* and *diagnostic(s)*
199 3,801 (Constantino and Charman 2016; Fakhoury 2015); and *autism* and *etiology* 1,639 (Risch
200 et al. 1999; Currenti 2010). After our eligibility assessment, there were only 3 publications
201 categorized in *treatment*, 9 in *diagnostics*, and only a single one in *etiology*. This result reveals a
202 very concerning state regarding ASD research in Brazil as very little scientific interest seems to
203 be directed toward this particular field.

204 What we believe Brazilian ASD research lacks most is an epidemiological assessment
205 of how occurrences may be distributed among region, age, comorbidities, and therapeutics.
206 Such an assessment has yet to be performed for this country, but worldwide, there have been 69
207 entries for this theme (Wing and Potter 2002; Newschaffer et al. 2007). An epidemiological
208 approach toward ASD patients in Brazil, and a comparison of this profile with other countries,
209 could facilitate possible new insights on causative effects (e. g., environmental, social, and
210 associated disease factors) and an understanding of the disease as a whole (Kim and Leventhal
211 2015; Duchan and Patel 2012).

212 The main focus of Brazilian studies for ASD is in diagnostics, mainly in translating,
213 adapting, and validating scaling tools. Although there are additional validated scales in
214 Brazilian Portuguese, they were not included in this review due to their lack of methodological
215 controls. This factor hinders reproducibility of these tools by themselves (Baker and Penny
216 2016). Additionally, some of the scales discussed in this review lack statistical basis. Many do
217 not report how sensible or specific the validated tool has become after translation, how
218 internally valid it is (Cronbach's $\alpha > 0.9$), or even if there is a general agreement by different
219 authorities (i.e., Cohen's κ) (Streiner et al. 2015). The absence of accurate analysis during
220 validation makes it difficult for professionals to select which tool is fundamentally best for their
221 application (Streiner et al. 2015). Thus, validation strategies in Brazilian studies need
222 improvement. Moreover, many scales do not present cut-off scores to newly-adapted validated
223 versions.

224 The main article on ASD treatment in Brazil was found to be a multicentric study from
225 a Chinese group; the other two articles reviewed multidisciplinary non-pharmacological
226 treatment (Hsia et al. 2014). There was no discussion of how different physicians (e. g.,
227 psychiatrists, neurologists, pediatricians) might proceed in a pharmacological approach in ASD
228 children or adults.(Imran et al. 2011) Moreover, there were no clinical studies to observe a new
229 pharmacological approach or family orientation for this disease (McPheeters et al. 2011;
230 Patterson et al. 2012).

Concerning etiology, only a single work, studying ASD in relation to parental age, was found in a retrospective study. We could not find any publications that traced genetically (Abrahams and Geschwind 2008), environmental (Hallmayer et al. 2011), or metabolic (Ming et al. 2012) causative effects to ASD with Brazilian subjects.

Our study does present some limitations. Firstly, we only used a single database, Scopus, which does not include theses and dissertations. Nevertheless, Scopus features extensive coverage and specificity when compared to other research engines such as Web of Science and Google Scholar (Falagas et al. 2008; Martín-Martín et al. 2018). Additionally, the search terms, although broad, may not have selected all articles that could apply to this systematic review if neither the title nor the abstract contained mention of Brazilian research subjects.

We analyzed studies that focused on autism in Brazil. We have not found an extensive sample and could not verify many groups seeking the etiology of autism in Brazilian subjects. A considerable share of the publications concerned validation of pre-existing scales in Brazilian Portuguese. Instead, the groups lack biochemical, genetics, or environmental perspectives of the disease in the country.

REFERENCES

- Abrahams, B. S., & Geschwind, D. H. (2008). Advances in autism genetics: on the threshold of a new neurobiology. *Nat Rev Genet*, 9(5), 341-355, doi:10.1038/nrg2346.
- Assumpção Jr., F. B., Kuczyński, E., Gabriel, M. G., & Rocca, C. (1999). Escala de avaliação de traços autísticos (ATA): validade e confiabilidade de uma escala para a detecção de condutas *Arquivos de Neuropsiquiatria*, 57(1), 23-29.
- Backes, B., Mônico, B. G., Bosa, C. A., & Bandeira, D. R. (2014). Psychometric properties of assessment instruments for autism spectrum disorder: A systematic review of Brazilian studies *Jornal Brasileiro de Psiquiatria*, 63(2), 154-164.
- Baker, M., & Penny, D. (2016). Is there a reproducibility crisis? *Nature*, 533(7604), 452-454.

258 Bara, T. S., Farias, A. C., Felden, E. P., & Cordeiro, M. L. (2018). Receiver operating
259 characteristic curve analysis of the Child Behavior Checklist and Teacher's Report Form
260 for assessing autism spectrum disorder in preschool-aged children. *Neuropsychiatr Dis*
261 *Treat*, 14, 95-102, doi:10.2147/NDT.S151185.

262 Bauman, M. L. (2010). Medical comorbidities in autism: challenges to diagnosis and treatment.
263 *Neurotherapeutics*, 7(3), 320-327, doi:10.1016/j.nurt.2010.06.001.

264 Becker, M. M., Wagner, M. B., Bosa, C. A., Schmidt, C., Longo, D., Papaleo, C., et al. (2012).
265 Translation and validation of Autism Diagnostic Interview-Revised (ADI-R) for autism
266 diagnosis in Brazil. *Arquivos de Neuropsiquiatria*, 70(3), 185-190.

267 Biederman, J., Petty, C. R., Fried, R., Wozniak, J., Micco, J. A., Henin, A., et al. (2010). Child
268 behavior checklist clinical scales discriminate referred youth with autism spectrum
269 disorder: a preliminary study. *J Dev Behav Pediatr*, 31(6), 485-490,
270 doi:10.1097/DBP.0b013e3181e56ddd.

271 Canabarro, R. C. C., Teixeira, M. C. T. V., & Schmidt, C. (2018). Translation and transcultural
272 adaptation of the self-efficacy scale for teachers of students with autism: Autism self-
273 efficacy scale for teachers (ASSET) *Revista Brasileira de Educação Especial*, 24(2),
274 229-246.

275 Castro-Souza, R. (2011). *Adaptação brasileira do M-CHAT (Modified Checklist for Autism in*
276 *Toddlers)*. Universidade de Brasília, Brasília.

277 Constantino, J. N., & Charman, T. (2016). Diagnosis of autism spectrum disorder: reconciling
278 the syndrome, its diverse origins, and variation in expression. *Lancet Neurol*, 15(3),
279 279-291, doi:10.1016/S1474-4422(15)00151-9.

280 Currenti, S. A. (2010). Understanding and determining the etiology of autism. *Cell Mol*
281 *Neurobiol*, 30(2), 161-171, doi:10.1007/s10571-009-9453-8.

282 dos Santos, P. A., Longo, D., Brandalize, A. P., & Schuler-Faccini, L. (2010). MTHFR C677T
283 is not a risk factor for autism spectrum disorders in South Brazil. *Psychiatr Genet*,
284 20(4), 187-189, doi:10.1097/YPG.0b013e32833a2220.

285 Duchan, E., & Patel, D. R. (2012). Epidemiology of autism spectrum disorders. *Pediatr Clin*
286 *North Am*, 59(1), 27-43, ix-x, doi:10.1016/j.pcl.2011.10.003.

287 Fakhoury, M. (2015). Autistic spectrum disorders: A review of clinical features, theories and
288 diagnosis. *Int J Dev Neurosci*, 43, 70-77, doi:10.1016/j.ijdevneu.2015.04.003.

289 Falagas, M. E., Pitsouni, E. I., Malietzis, G. A., & Pappas, G. (2008). Comparison of PubMed,
290 Scopus, Web of Science, and Google Scholar: strengths and weaknesses. *FASEB J*,
291 22(2), 338-342, doi:10.1096/fj.07-9492LSF.

292 Goin-Kochel, R. P., Porter, A. E., Peters, S. U., Shinawi, M., Sahoo, T., & Beaudet, A. L.
293 (2009). The MTHFR 677C-->T polymorphism and behaviors in children with autism:
294 exploratory genotype-phenotype correlations. *Autism Res*, 2(2), 98-108,
295 doi:10.1002/aur.70.

296 Goulart, J. C., Blanco, M. B., & Neto, J. C. (2017). The digital game in touch technology as a
297 learning tool for the Autistic Child. *Espacios*, 38(60), 15.

298 Graf, W. D., Miller, G., Epstein, L. G., & Rapin, I. (2017). The autism "epidemic": Ethical,
299 legal, and social issues in a developmental spectrum disorder. *Neurology*, 88(14), 1371-
300 1380, doi:10.1212/WNL.0000000000003791.

301 Gray, K. M., Tonge, B. J., & Sweeney, D. J. (2008). Using the autism Diagnostic Interview-
302 Revised and the Autism Diagnostic Observation Schedule with young children with
303 developmental delay: evaluating diagnostic validity. *Journal of Autism and*
304 *Developmental Disorders*, 38(4), 657-667.

305 Hallmayer, J., Cleveland, S., Torres, A., Phillips, J., Cohen, B., Torigoe, T., et al. (2011).
306 Genetic heritability and shared environmental factors among twin pairs with autism.
307 *Arch Gen Psychiatry*, 68(11), 1095-1102, doi:10.1001/archgenpsychiatry.2011.76.

308 Havdahl, K. A., von Tetzchner, S., Huerta, M., Lord, C., & Bishop, S. L. (2016). Utility of the
309 Child Behavior Checklist as a Screener for Autism Spectrum Disorder. *Autism Res*,
310 9(1), 33-42, doi:10.1002/aur.1515.

311 Hsia, Y., Wong, A. Y., Murphy, D. G., Simonoff, E., Buitelaar, J. K., & Wong, I. C. (2014).
312 Psychopharmacological prescriptions for people with autism spectrum disorder (ASD):

313 a multinational study. *Psychopharmacology (Berl)*, 231(6), 999-1009,
314 doi:10.1007/s00213-013-3263-x.

315 Imran, N., Chaudry, M. R., Azeem, M. W., Bhatti, M. R., Choudhary, Z. I., & Cheema, M. A.
316 (2011). A survey of Autism knowledge and attitudes among the healthcare professionals
317 in Lahore, Pakistan. *BMC Pediatr*, 11, 107, doi:10.1186/1471-2431-11-107.

318 Kagohara, D. M., van der Meer, L., Ramdoss, S., O'Reilly, M. F., Lancioni, G. E., Davis, T. N.,
319 et al. (2013). Using iPods((R)) and iPads((R)) in teaching programs for individuals with
320 developmental disabilities: a systematic review. *Res Dev Disabil*, 34(1), 147-156,
321 doi:10.1016/j.ridd.2012.07.027.

322 Kim, Y. S., & Leventhal, B. L. (2015). Genetic epidemiology and insights into interactive
323 genetic and environmental effects in autism spectrum disorders. *Biol Psychiatry*, 77(1),
324 66-74, doi:10.1016/j.biopsych.2014.11.001.

325 Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism Diagnostic Interview-Revised: a revised
326 version of a diagnostic interview for caregivers of individuals with possible pervasive
327 developmental disorders. *Journal of Autism and Developmental Disorders*, 24(5), 259-
328 285.

329 Losapio, M. F., & Pondé, M. P. (2008). Tradução para o português da escala M-CHAT para
330 rastreamento precoce de autismo. *Revista de Psiquiatria do Rio Grande do Sul*, 30(3),
331 221-229.

332 Maia, F. A., Almeida, M. T. C., Alves, M. R., Bandeira, L. V. S., Silva, V. B. D., Nunes, N. F.,
333 et al. (2018). [Autism spectrum disorder and parents' age: a case-control study in
334 Brazil]. *Cad Saude Publica*, 34(8), e00109917, doi:10.1590/0102-311X00109917.

335 Marques, D. F., & Bosa, C. A. (2015). Protocolo de Avaliação de Crianças com Autismo:
336 Evidências de Validade de Critério. *Psicologia: Teoria e Pesquisa*, 31(1), 43-51.

337 Marteleto, M. R., & Pedromonico, M. R. (2005a). Validity of Autism Behavior Checklist
338 (ABC): preliminary study. *Brazilian Journal of Psychiatry*, 27(4), 295-301, doi:/S1516-
339 44462005000400008.

340 Marteleto, M. R., & Pedromonico, M. R. (2005b). Validity of Autism Behavior Checklist
341 (ABC): preliminary study. *Braz J Psychiatry*, 27(4), 295-301, doi:/S1516-
342 44462005000400008.

343 Martín-Martín, A., Orduna-Malea, E., Thelwall, M., & López-Cózar, E. D. (2018). Google
344 Scholar, Web of Science, and Scopus: a systematic comparison of citations in 252
345 subject categories. *Journal of Infometrics*, 12(4), 1160-1177,
346 doi:10.1016/j.joi.2018.09.002.

347 McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., et al.
348 (2011). A systematic review of medical treatments for children with autism spectrum
349 disorders. *Pediatrics*, 127(5), e1312-1321, doi:10.1542/peds.2011-0427.

350 Ming, X., Stein, T. P., Barnes, V., Rhodes, N., & Guo, L. (2012). Metabolic perturbation in
351 autism spectrum disorders: a metabolomics study. *J Proteome Res*, 11(12), 5856-5862,
352 doi:10.1021/pr300910n.

353 Moss, J., Magiati, I., Charman, T., & P., H. (2008). Stability of the autism diagnostic interview-
354 revised from pre-school to elementary school age in children with autism spectrum
355 disorders. *Journal of Autism and Developmental Disorders*, 38(6), 1081-1091.

356 Murphy, C. M., Wilson, C. E., Robertson, D. M., Ecker, C., Daly, E. M., Hammond, N., et al.
357 (2016). Autism spectrum disorder in adults: diagnosis, management, and health services
358 development. *Neuropsychiatr Dis Treat*, 12, 1669-1686, doi:10.2147/NDT.S65455.

359 Murray, M. L., Hsia, Y., Glaser, K., Simonoff, E., Murphy, D. G., Asherson, P. J., et al. (2014).
360 Pharmacological treatments prescribed to people with autism spectrum disorder (ASD)
361 in primary health care. *Psychopharmacology (Berl)*, 231(6), 1011-1021,
362 doi:10.1007/s00213-013-3140-7.

363 Newschaffer, C. J., Croen, L. A., Daniels, J., Giarelli, E., Grether, J. K., Levy, S. E., et al.
364 (2007). The epidemiology of autism spectrum disorders. *Annu Rev Public Health*, 28,
365 235-258, doi:10.1146/annurev.publhealth.28.021406.144007.

366 Nunes, D., & Walter, C. (2018). AAC and Autism in Brazil: A Descriptive Review.
367 *International Journal of Disability, Development and Education*, Article in Press.

368 Park, H. R., Lee, J. M., Moon, H. E., Lee, D. S., Kim, B. N., Kim, J., et al. (2016). A Short
369 Review on the Current Understanding of Autism Spectrum Disorders. *Exp Neurobiol*,
370 25(1), 1-13, doi:10.5607/en.2016.25.1.1.

371 Pasca, S. P., Dronca, E., Kaucsar, T., Craciun, E. C., Endreffy, E., Ferencz, B. K., et al. (2009).
372 One carbon metabolism disturbances and the C677T MTHFR gene polymorphism in
373 children with autism spectrum disorders. *J Cell Mol Med*, 13(10), 4229-4238,
374 doi:10.1111/j.1582-4934.2008.00463.x.

375 Patterson, S., Smith, V., & Jelen, M. (2012). Autism spectrum disorders: information for
376 pediatricians supporting families of young children on the spectrum. *Adv Exp Med Biol*,
377 724, 51-60, doi:10.1007/978-1-4614-0653-2_4.

378 Pereira, A., Riesgo, R. S., & Wagner, M. B. (2008). Autismo infantil: a validação da Childhood
379 Autism Rating Scale para uso no Brasil. *The Journal of Pediatrics*, 84(6), 487-494.

380 Puleo, C. M., Schmeidler, J., Reichenberg, A., Kolevzon, A., Soorya, L. V., Buxbaum, J. D., et
381 al. (2012). Advancing paternal age and simplex autism. *Autism*, 16(4), 367-380,
382 doi:10.1177/1362361311427154.

383 Ribeiro, S. H., Paula, C. S., Bordini, D., Mari, J. J., & Caetano, S. C. (2017). Barriers to early
384 identification of autism in Brazil. *Braz J Psychiatry*, 39(4), 352-354, doi:10.1590/1516-
385 4446-2016-2141.

386 Risch, N., Spiker, D., Lotspeich, L., Nouri, N., Hinds, D., Hallmayer, J., et al. (1999). A
387 genomic screen of autism: evidence for a multilocus etiology. *Am J Hum Genet*, 65(2),
388 493-507, doi:10.1086/302497.

389 Ruble, L. A., Toland, M. D., Birdwhistell, J. L., McGrew, J. H., & Usher, E. L. (2013).
390 Preliminary Study of the Autism Self-Efficacy Scale for Teachers (ASSET). *Res Autism*
391 *Spectr Disord*, 7(9), 1151-1159, doi:10.1016/j.rasd.2013.06.006.

392 Sato, F. P., Paula, C. S., Lowenthal, R., Nakano, E. Y., Brunoni, D., Schwartzman, J. S., et al.
393 (2009). Instrument to screen cases of pervasive developmental disorder: a preliminary
394 indication of validity. *Brazilian Journal of Psychiatry*, 31(1), 30-33.

395 Seize, M. M., & Borsa, J. C. (2017). Instrumentos para rastreamento de sinais precoces do
396 autismo: Revisão sistemática. *Psico-USF*, 22(1), 161-176.

397 Streiner, D. L., Norman, G. R., & Cairney, J. (2015). Selecting the items. In D. L. Streiner, G.
398 R. Norman, & J. Cairney (Eds.), *Health Measurement Scales: A practical guide to their*
399 *development and use*. United Kingdom: Oxford University Press.

400 Volkmar, F., Siegel, M., Woodbury-Smith, M., King, B., McCracken, J., State, M., et al. (2014).
401 Practice parameter for the assessment and treatment of children and adolescents with
402 autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry*, 53(2), 237-257,
403 doi:10.1016/j.jaac.2013.10.013.

404 Wing, L., & Potter, D. (2002). The epidemiology of autistic spectrum disorders: is the
405 prevalence rising? *Ment Retard Dev Disabil Res Rev*, 8(3), 151-161,
406 doi:10.1002/mrdd.10029.

407 Zhubi, A., Cook, E. H., Guidotti, A., & Grayson, D. R. (2014). Epigenetic mechanisms in
408 autism spectrum disorder. *Int Rev Neurobiol*, 115, 203-244, doi:10.1016/B978-0-12-
409 801311-3.00006-8.

410 Zito, J. M., Safer, D. J., de Jong-van den Berg, L. T., Janhsen, K., Fegert, J. M., Gardner, J. F.,
411 et al. (2008). A three-country comparison of psychotropic medication prevalence in youth.
412 *Child Adolesc Psychiatry Ment Health*, 2(1), 26, doi:10.1186/1753-2000-2-26.

413 **FIGURE CAPTIONS**

414 *Figure 1.* Flow diagram describing the methodology of study selection according to the
415 PRISMA statement.

416

Figure 1

417

418 Table 1. Summary of the findings in this review.

Authors	Title	Study type	Main findings
(Hsia et al. 2014)	Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): A multinational study	Treatment	How drugs have been prescribed for the treatment of ASD around the world, including in Brazil, which mainly uses risperidone, as opposed to haloperidol in Asia or methylphenidate in the UK.
(Sato et al. 2009)	Instrument to screen cases of pervasive developmental disorder-a preliminary indication of validity [Instrumento para rastreamento dos casos de transtorno invasivo do desenvolvimento-estudo preliminar de validação]	Diagnostics/Scale	Validates the Autism Screening Questionnaire (ASQ) to the Brazilian Portuguese language.
(dos Santos et al. 2010)	MTHFR C677T is not a risk factor for autism spectrum disorders in South Brazil	Diagnostics	Concludes that the C677T polymorphism in MTHFR is not associated with ASD in the South of Brazil.
(Becker et al. 2012)	Translation and validation of Autism Diagnostic Interview-Revised (ADI-R) for autism diagnosis in Brazil [Tradução e validação da ADI-R (Autism Diagnostic Interview-Revised) para diagnóstico de autismo no Brasil]	Diagnostics/Scale	Validates the Autism Diagnostic Interview-Revised (ADI-R) to the Brazilian Portuguese language.
(Ribeiro et al. 2017)	Barriers to early identification of autism in Brazil	Diagnostics	Indicates the presence of barriers for the diagnoses in ASD children under 36 months of age.
(Backes et al. 2014)	Psychometric properties of assessment instruments for autism spectrum disorder: A systematic review of Brazilian studies [Propriedades psicométricas de instrumentos de avaliação do transtorno do espectro do autismo: Uma revisão sistemática de estudos Brasileiros]	Diagnostics/Scale	Compares the different validated scales in Brazilian Portuguese and concludes that few of them can precisely assist diagnosis.
(Marques and Bosa 2015)	Evaluation protocol for children with Autism: Evidence of criterion validity [Protocolo de avaliação de crianças com Autismo: Evidências de validade de critério]	Diagnostics/Scale	Presents a modification of an evaluation tool for ASD children in Brazilian Portuguese: the <i>Protocolo de Observação para Crianças com</i>

<i>Suspeita de Transtornos do Espectro do Autismo (PRO-TEA)</i>			
Translation and transcultural adaptation of the self-efficacy scale for teachers of students			
(Canabarro et al. 2018)	with autism: Autism self-efficacy scale for teachers (ASSET) [Tradução e adaptação transcultural da escala de avaliação de autoeficácia de professores de alunos com autismo: Autism self-efficacy scale for teachers (ASSET)]	Diagnostics/Scale	Validates the Autism Self-Efficacy Scale for Teachers (ASSET) to the Brazilian Portuguese language.
(Nunes and Walter 2018)	AAC and Autism in Brazil: A Descriptive Review	Treatment	Reviews how the use of Augmentative and Alternative Communication (AAC) has been improving and can improve the treatment of ASD children in Brazil.
(Maia et al. 2018)	Autism spectrum disorder and parents' age: A case-control study in Brazil [Transtorno do espectro do autismo e idade dos genitores: Estudo de caso-controle no Brasil] [Trastorno del espectro de autismo y edad de los progenitores: Estudio de caso-control en Brasil]	Etiology	Investigates and compares how the maternal and paternal age of conception influences ASD onset.
(Bara et al. 2018)	Receiver operating characteristic curve analysis of the child behavior checklist and teacher's report form for assessing autism spectrum disorder in preschool-aged children	Diagnostics/Scale	Studies the efficiency of Child Behavior Checklist (CBCL) and Caregiver-Teacher's Report Form (C-TRF), and correlates both of them.
(Goulart et al. 2017)	The digital game in touch technology as a learning tool for the Autistic Child [O jogo digital em tecnologia touch como instrumento de aprendizagem para Criança Autista]	Treatment	Reviews dissertations and thesis containing information on how touch technology may improve cognitive treatment on ASD children.
(Seize and Borsa 2017)	Instrumentos para rastreamento de sinais precoces do autismo: Revisão sistemática [Instruments to screen the early signs of autism: Systematic review]	Diagnostics/Scale	Reviews the scaling tools that can assist the diagnosis in children under 36 months of age.

Table 2. Overview of statistics regarding validated scales that appeared in our search.

Study	Scale	Sensitivity ^a	Specificity ^b	Cronbach's α ^c	Median Cohen's κ coefficient ^d
(Sato et al. 2009)	ASQ	92.5%	95.5%	0.895	Not reported
(Becker et al. 2012)	ADI-R	100%	100%	0.967	0.824
(Marques and Bosa 2015)	PRO-TEA	Not reported	Not reported	Not reported	Not reported
(Bara et al. 2018)	CBCL	53.3%	Not reported	Not reported	Not reported
(Bara et al. 2018)	C-TRF	80.6%	71.8%	Not reported	Not reported
(Marteleto and Pedromonico 2005b) from (Backes et al. 2014)	ABC	92.1%	92.6%	Not reported	Not reported
(Assumpção Jr. et al. 1999) from (Backes et al. 2014)	ATA	96.0%	Not reported	0.710	Not reported
(Pereira et al. 2008) from (Backes et al. 2014)	CARS	Not reported	Not reported	0.820	0.900
(Castro-Souza 2011) from (Backes et al. 2014)	M-CHAT	94.0%	91.0%	0.950	Not reported

^aCorresponds to how a test correctly identifies the individuals with the disease.

^bRepresents how a test distinguishes the individuals with the disease from those without.

^cThe α represents an internal consistency estimate of the reliability of test scores. Above 0.9 is generally considered acceptable (Streiner et al. 2015).

^dVerifies how answers agree among different raters. "0" implies no agreement of answers, "1" represents the complete agreement of answers.